Leorah Ross

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial

M. Balwani, T. Cox, T. Burrow, 2015, The Lancet.

Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

S. Packman, H. Baris, A. Mehta, 2015, JAMA.

Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.

G. Pastores, A. Zimran, H. Rosenbaum, 2014, Blood cells, molecules & diseases.

Angiopoietin-1 protects the adult vasculature against plasma leakage

N. Glazer, G. Yancopoulos, D. McDonald, 2000, Nature Medicine.

Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database

J. Keutzer, So-Fai Tsang, Shirali Pandya, 2022, Drug Safety.

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1

J. Ibrahim, M. Peterschmitt, Leorah H. Ross, 2020, Molecular genetics and metabolism reports.

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

G. Yancopoulos, A. Byrne, George D Yancopoulos, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.

J. Ruskin, P. Maison-Blanche, J. Msihid, 2020, Molecular genetics and metabolism.

Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.

J. Ibrahim, Yong Xue, N. Thibault, 2020, Molecular genetics and metabolism.

ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results

M. Balwani, E. Lukina, J. Angell, 2015 .

ENGAGE — A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: Results after 18 months

S. Packman, M. Balwani, P. Mistry, 2015 .